{"prompt": "['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 79 of 122', 'of care alone who complete the OLFC after 12 months of observation and who complete the', 'exit visit.', 'The AR101 per protocol population may be defined if it is sufficiently different from the', 'AR101 completer population. The AR101 per protocol population will include all subjects in', 'the AR101 completer population who have no major protocol deviations. The standard of', 'care per protocol population will be defined as all subjects in the standard of care completer', 'population who have no major protocol deviations.', 'The safety population will be defined as all subjects who receive any randomized study', 'treatment (ie, who receive any part of 1 dose of study product and complete 1 study visit if', 'assigned to AR101 treatment or who complete 1 study visit after the screening visit if', 'assigned to standard of care alone). The safety population will be used for all safety analyses', 'and analyzed according to treatment received.', '10.3 Determination of Sample Size', 'This study will use multiple HRQOL questionnaires to assess changes across time in the', 'HRQOL of subjects receiving AR101 treatment versus standard of care alone, and their', 'parents/caregivers.', 'The sample size for this study is based on estimates for the FAQLQ-PF. A sample size of', '144 subjects randomly assigned in a ratio of 2:1 to AR101 treatment (96 subjects) or standard', 'of care alone (48 subjects) provides at least 80% power to detect a treatment difference', 'of 0.75 in the adjusted mean total FAQLQ-PF scores at 18 months. The sample size', 'calculation is based on an alpha of 0.05 and tests are assumed to be 2-sided. The common', 'standard deviation is assumed to be 1.5 (DunnGalvin, 2010). Approximately 25% of subjects', 'are estimated to drop out or discontinue early from the study. Therefore, approximately', '200 subjects (134, AR101 treatment; 67, standard of care alone) will be randomly assigned to', 'study treatment.', '10.4 Interim Analyses', 'No interim analyses are planned.', '10.5 Analyses of HRQOL', 'The primary objective assesses HRQOL of subjects receiving AR101 treatment versus', 'standard of care alone for approximately 18 months.', 'No single endpoint is specified as primary because the study is not designed or intended to', 'support a labelling claim.', 'The primary analyses will be on a family of proxy- and self-reported disease-specific', 'HRQOL measures that assess the HRQOL of the peanut-allergic subject. The ITT', 'population will be used for these analyses. Data summaries will be presented across time and', 'accompanied by inferential analyses.']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 80 of 122', 'The relevant disease-specific HRQOL questionnaires (FAQLQ-PF, FAQLQ-PFT,', 'FAQLQ-CF, FAQLQ-TF, FAIM-PF, FAIM-PFT, FAIM-CF, and FAIM-TF) are described in', 'Sections 9.1.1 and 9.1.2.', 'As the number of items and domains vary by instrument, the exact algorithms used to', 'calculate the total and domain scores, where defined, and the rules for handling missing data', 'will be described in the statistical analysis plan. Missing data for follow-up questionnaires', 'completed after early discontinuation will not preclude the execution of the primary analyses.', 'Data will also be summarized separately by age group as appropriate for the questionnaire', 'evaluated.', 'Descriptive statistics for the FAQLQ-PF questionnaire, completed by the parent/caregiver of', 'subjects aged 4 to 12 years, will be presented for the total score, domain scores, individual', 'questions, and changes from baseline across time.', 'As a supporting analysis, analysis of covariance (ANCOVA) will be performed on the ITT', 'population to assess the change from baseline in the total FAQLQ-PF score and each of the', 'domain scores at study exit (approximately 18 months). Adjustment will be made for', 'treatment and country as main effects; baseline score will be fitted as a covariate.', 'The least squares mean of the treatment differences for AR101 treatment versus standard of', 'care alone will be presented together with the corresponding 2-sided 95% CI and p-value.', 'The null (Ho) and alternative (H1) hypotheses for these analyses (ie, total FAQLQ-PF score', 'and each domain score) are as follows:', 'Ho: there is no difference between groups in the mean change from baseline for', 'AR101 treatment and standard of care alone', 'H1: there is a difference between groups in the mean change from baseline for AR 101', 'treatment and standard of care alone', 'Such that:', 'Ho HAR101 = standard of care alone', 'H1 HAR101 # standard of care alone', 'where HAR101 is estimated by the mean change from baseline from the ANCOVA in', 'the AR101 treatment group and Ustandard of care alone by the mean change from baseline', 'from the ANCOVA in the standard of care alone group', 'These analyses may be repeated for the completer population and the per protocol population', '(if defined).', 'Similar data presentations and analyses will be provided for the other disease-specific', 'HRQOL questionnaires (FAQLQ-PFT, FAQLQ-CF, FAQLQ-TF, FAIM-PF, FAIM-PFT,', 'FAIM-CF, and FAIM-TF).', 'Full details will be provided in the statistical analysis plan.']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 81 of 122', '10.6 Analysis of Other Questionnaires', 'Details of the analyses for other questionnaires and bespoke questions will be provided in the', 'statistical analysis plan. Other questionnaires include the EQ-5D, FAQL-PB, HADS, and', 'TSQM-9. Bespoke questions include global assessment of HRQOL, assessment of control of', 'peanut allergy and confidence in managing allergic reactions, assessment of experiences', 'related to food challenges, and assessment of experience and satisfaction with AR101', 'treatment at study exit.', '10.7 Analysis of Efficacy', 'Desensitization response rates during the OLFC will be compared between treatment groups', 'as follows:', 'The proportion of subjects tolerating a single dose of 300 mg (443 mg cumulative) of', 'peanut protein with no or mild symptoms in the OLFC after approximately 12 months', 'of study treatment', 'The proportion of subjects tolerating a single dose of 600 mg (1043 mg cumulative)', 'of peanut protein with no or mild symptoms in the OLFC after approximately', '12 months of study treatment', 'The proportion of subjects tolerating a single dose of 1000 mg (2043 mg cumulative)', 'of peanut protein with no or mild symptoms in the OLFC after approximately', '12 months of study treatment', 'The ITT population and Fisher exact test will be used for these analyses. For each endpoint,', 'subjects tolerating the indicated single challenge dose of peanut protein will be considered', 'responders; subjects who do not tolerate the indicated single challenge dose of peanut protein', 'will be considered nonresponders. Nonresponders will also include subjects who withdraw', 'consent or discontinue early before having the OLFC, and subjects who do not reach the', '300 mg/day dose or maintain a 300 mg daily dose of study product for 12 months.', 'Desensitization response rates and associated 95% CIs will be presented for each treatment', 'group using exact Clopper-Pearson CIs. The 95% CI for the treatment difference', '(desensitization rate for AR101 treatment minus desensitization rate for standard of care', 'alone) will be based on exact unconditional confidence limits using the score statistic.', 'Additional efficacy endpoints will be assessed as follows:', 'The maximum dose reached with no or mild symptoms at the OLFC will be assessed by', 'tabulating the number and percentage of subjects by maximum dose at the OLFC and by', 'treatment group. The Cochran-Mantel-Haenszel statistics with equally spaced scores (row', 'mean score differences statistic) stratified by country will be used to test for a treatment', 'difference.', 'The maximum severity of symptoms occurring at each challenge dose of peanut protein', 'during the OLFC will be assessed by tabulating the number and percentage of subjects by']", "completion": ""}